Keywords: Small-molecule cancer drugs, Market forecasts, Visiongain, Novartis, Glivec, Gleevec
Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain
Article | 09 January 2013
The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in 2016, compared with $21.7 billion in 2011, according to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
